Pharmaceuticals News and Research

RSS

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant.

24 May 2013

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection.

24 May 2013

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

23 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

Innovative nebulizer to treat cystic fibrosis developed by Cambridge Consultants

Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease. Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a revolutionary new aerosol delivery system. It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.

23 May 2013

Arthritis Research UK awards Cardiff researchers a grant to develop new drugs to treat osteoarthritis

Medical research charity Arthritis Research UK has awarded a team of researchers at Cardiff University a grant of £200,000 to investigate new drugs to treat early onset osteoarthritis. The team will investigate a new therapy to reduce the risk of developing osteoarthritis.

23 May 2013

As Hill panels focus on Medicare, marketplace examines how Part D changed the pharmaceutical industry

Medicare is a topic of conversation on Capitol Hill as a Senate committee holds a hearing on the Medicare Part D drug program. Meanwhile, on the House side, members of the Ways and Means Health Subcommittee heard testimony on patient cost-sharing that triggered a broad discussion of health care incentives within the program.

23 May 2013

Cognoptix' SAPPHIRE II eye test identifies Alzheimer's disease patients via Ab signature in the eyes

Cognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes in a 10-subject proof-of-concept clinical trial.

23 May 2013

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects.

23 May 2013

Prosonix commences Phase 2 clinical study of PSX1002 for treatment of moderate to severe COPD

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe chronic obstructive pulmonary disease.

23 May 2013

Study: Regardless of pain, women are more likely to be prescribed pain-relieving drugs

Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is influenced by socioeconomic inequality between genders in the Autonomous Community in which the patient resides.

22 May 2013

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.

22 May 2013

Alzheimer's disease: Researchers find new drug to prevent, treat the disease

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.

22 May 2013

Newly discovered immune protein has potential to stop or reverse type 1 diabetes

Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.

21 May 2013

Improving health care, reducing costs possible by breaking up physicians and drug company relationship

A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, more costly and often unnecessary prescription drugs.

21 May 2013

Groundbreaking germ-fighting vaccine research to be presented at National Biotechnology Conference

A novel vaccine study from South Dakota State University will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' National Biotechnology Conference.

21 May 2013

Research explores pharmaceutical advances for IBS, hepatitis C

Research presented at Digestive Disease Week explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea and hepatitis C.

21 May 2013

Scientists design 'fishing' technique to show health benefits of foods

New research suggests that a compound abundant in the Mediterranean diet takes away cancer cells' "superpower" to escape death.

21 May 2013

New breakthrough in progeria treatment

Pharmaceuticals that inhibit a specific enzyme may be useful in treating progeria, or accelerated aging in children. A new study performed at the Sahlgrenska Academy, University of Gothenburg, Sweden, indicates that the development of progeria in mice was inhibited upon reducing the production of this enzyme.

21 May 2013

Pharmaceuticals News and Research

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

Innovative nebulizer to treat cystic fibrosis developed by Cambridge Consultants

Arthritis Research UK awards Cardiff researchers a grant to develop new drugs to treat osteoarthritis

As Hill panels focus on Medicare, marketplace examines how Part D changed the pharmaceutical industry

Cognoptix' SAPPHIRE II eye test identifies Alzheimer's disease patients via Ab signature in the eyes

University of Granada researchers patent new treatment for acne

Prosonix commences Phase 2 clinical study of PSX1002 for treatment of moderate to severe COPD

Study: Regardless of pain, women are more likely to be prescribed pain-relieving drugs

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Alzheimer's disease: Researchers find new drug to prevent, treat the disease

Newly discovered immune protein has potential to stop or reverse type 1 diabetes

Improving health care, reducing costs possible by breaking up physicians and drug company relationship

Groundbreaking germ-fighting vaccine research to be presented at National Biotechnology Conference

Research explores pharmaceutical advances for IBS, hepatitis C

Scientists design 'fishing' technique to show health benefits of foods

New breakthrough in progeria treatment

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence